isirv

Q1 2023

Neuraminidase Inhibitors

Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1,048 patients hospitalised during the 2016-17 and 2017-18 influenza seasons…read more

Endonuclease and other Polymerase Inhibitors

Carboxylic Acid Isostere Derivatives of Hydroxypyridinones as Core Scaffolds for Influenza Endonuclease Inhibitors…read more

Prescription factors influencing baloxavir prescription during the 2018/2019 and 2019/2020 seasons: a administrative database study in Japan…read more

New Drug Discovery

Antiviral activities of plant-derived indole and β-carboline alkaloids against human and avian influenza viruses…read more

Inhibition of cellular RNA methyltransferase abrogates influenza virus capping and replication…read more

Synthesis and structure-activity optimization of 7-azaindoles containing aza-β-amino acids targeting the influenza PB2 subunit…read more

Clinical Trials & Case Studies

Lessons from resistance analysis in clinical trials of IV zanamivir…read more

Comparative effectiveness of oseltamivir versus peramivir for hospitalized children (aged 0-5 years) with influenza infection…read more

Baloxavir safety and clinical and virologic outcomes in influenza virus-infected pediatric patients by age group: age-based pooled analysis of two pediatric studies conducted in Japan…read more

Influenza Antiviral Use in Patients Hospitalized With Laboratory-Confirmed Influenza in the United States, FluSurv-NET, 2015–2019…read more

Reviews

Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy…read more

Antiviral News prepared by: Dr Jeremy C. Jones, Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, TN, USA